Literature DB >> 12765173

Roy Hertz, M.D. (1909-2002): the cure of choriocarcinoma and its impact on the development of chemotherapy for cancer.

Jonathan P Yarris1, Alan J Hunter.   

Abstract

Dr. Roy Hertz is one of two scientists credited with discovering the first medical cure of a solid cancer. This paper presents a biographical history of Dr. Hertz and discusses his roles in the discovery of a cure for choriocarcinoma and as a pioneer for future research in cancer chemotherapy. This biography not only serves as a testament to the pioneering individuals in the field of chemotherapeutics but also represents the unique blend of medical, pharmacological, and physiological histories that led to the profound discovery. The timing and significance of the work of Drs. Hertz and Li cannot be overestimated. Their discovery was a spectacular success, demonstrating proof of the principle that chemotherapy can cure metastatic cancer and that an almost uniformly fatal cancer in young patients could be cured with a single chemotherapeutic agent, which stands as one of the greatest achievements in cancer research.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12765173     DOI: 10.1016/s0090-8258(03)00110-0

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  3 in total

1.  Cutaneous metastases of infantile choriocarcinoma can mimic infantile hemangioma both clinically and radiographically.

Authors:  Logan R Dance; Apurvi R Patel; Mittun C Patel; Patricia Cornejo; Cory M Pfeifer
Journal:  Pediatr Radiol       Date:  2018-03-24

2.  The evolution of methotrexate as a treatment for ectopic pregnancy and gestational trophoblastic neoplasia: a review.

Authors:  Monika M Skubisz; Stephen Tong
Journal:  ISRN Obstet Gynecol       Date:  2012-02-19

3.  A deadly prescription: combination of methotrexate and trimethoprim-sulfamethoxazole.

Authors:  Mohsin Hamid; Bilal Lashari; Irfan Ahsan; Ida Micaily; Usman Sarwar; Joseph Crocetti
Journal:  J Community Hosp Intern Med Perspect       Date:  2018-06-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.